Trevogrumab
From WikiMD's WELLNESSPEDIA
| Trevogrumab | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 1429201-24-0 |
| PubChem | |
| DrugBank | |
| ChemSpider | none |
| KEGG | D11242 |
Trevogrumab (INN[1]) (REGN1033) is a human monoclonal antibody designed for the treatment of muscle atrophy due to orthopedic disuse and sarcopenia.
This drug was developed by Regeneron Pharmaceuticals, Inc.[2]
References[edit]
- ↑ World Health Organization."International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113".WHO Drug Information.2015;29(2)Full text.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Trevogrumab, American Medical Association.
| Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
